Why TRAX rose 33.6% on Oct 12 2026: positive phase 1b data
TRAX+33.6%on Mon Oct 12 2026
First Tracks Biotherapeutics, Inc. Ordinary Shares was up 33.6% on the day at $42.55, ranked #4 on 46.5× its usual five-minute volume, when TapeRank recorded this spike at 07:02 ET during the pre-market session. TapeRank recorded 2 events for TRAX that day, between 04:01 and 07:02 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 04:01 ETUNEXPLAINED MOVE · PRE-MARKET
$36.71 · ▲ 15.3% ON THE DAY · — 5M RVOL · RANK #19
UNEXPLAINEDNO FILINGS · RULETRAX is up 15.3% on the day on no measurable its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.
WHYNo filings or headlines within 24 hours of the move.ANALYZED 04:01 ET · <1 MIN AGO · RULE, NO MODELTHE ROW AND SESSION LEVELS AT 04:01 ET
LAST36.71DAY▲ 15.3%5 MIN▲ 1.30%5M RVOL—5M $VOL$26KFLOAT—RANK#19SESSIONPRE-MARKETVWAP36.62HOD36.71LOD36.24OR HIGH—OR LOW—PREV CLOSE31.85PM HIGH36.71PM LOW36.24GAP▲ 15.26% (indicated)— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 07:02 ETMOVER · PRE-MARKET
$42.55 · ▲ 33.6% ON THE DAY · 46.5× 5M RVOL · RANK #4
JUSTIFIEDCONFIDENCE5/5TRAX is up 53.9% pre-market, with an additional 16.69% surge in five minutes, after reporting statistically significant and clinically meaningful Phase 1b celiac-disease results. The efficacy signal, symptom benefit, and absence of observed safety issues provide a concrete catalyst capable of supporting a major biotech repricing.
WHYA 53.9% move is large, but it is proportionate to positive, statistically significant Phase 1b efficacy data in a clinical-stage biotech with no disclosed dilution in the supplied filings.ANALYZED 07:06 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 07:02 ET
LAST42.55DAY▲ 33.6%5 MIN▲ 16.58%5M RVOL46.5×5M $VOL$531KFLOAT—RANK#4SESSIONPRE-MARKETVWAP37.48HOD42.55LOD34.97OR HIGH—OR LOW—PREV CLOSE31.85PM HIGH42.55PM LOW34.97GAP▲ 33.59% (indicated)— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $39.45, +23.9% on the previous close of $31.85
- 09:30 ETRegular-session high, $40.50
- 15:59 ETRegular-session low, $33.02
- 15:59 ETLast trade of the regular session, $33.93, +6.5% on the previous close of $31.85
- Volume: 5.8M shares in regular hours, 1.4M before the open
TRAX opened at $39.45 and reached $40.50 immediately, after TapeRank recorded an unexplained move at $36.71 before the open and then a $42.55 move ranked #4. TapeRank’s read initially tied the pre-market surge to positive Phase 1b celiac-disease data, citing statistically significant and clinically meaningful results, symptom benefit and no observed safety issues, but it also found no filings or headlines within 24 hours of the recordings and therefore marked the move unexplained by rule. With no halts, the stock reversed through the session, reaching a $33.02 low before finishing at $33.93.
WRITTEN THU OCT 15 2026 18:04 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
No SEC filings or wire news in the 24 hours before this was recorded. A move on news that never reached the wire shows nothing here, which is what UNEXPLAINED means.
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list